Financial relationships with industry among national comprehensive cancer network guideline authors

JAMA Oncology

Volumn 2, Issue 12, 2016, Pages 1628-1631

  Mitchell, Aaron P ^a,b   Basch, Ethan M ^a,b   Dusetzina, Stacie B ^b,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c University of North Carolina   (United States)

^d IL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT; GOVERNMENT; HUMAN; MANPOWER; NEOPLASMS; PHYSICIAN; PRACTICE GUIDELINE; UNITED STATES;

CENTERS FOR MEDICARE AND MEDICAID SERVICES (U.S.); CONFLICT OF INTEREST; DRUG INDUSTRY; FINANCIAL SUPPORT; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; PHYSICIANS; UNITED STATES;

EID: 84994559097     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.2710     Document Type: Article

References (15)

1. Institute of Medicine (US) Committee on Conflict of Interest in Medical Research, Education, and Practice. In: Lo B, Field MJ, eds. Conflict of Interest in Medical Research, Education, and Practice. Washington, DC: National Academies Press (US); 2009, http://www.ncbi.nlm.nih.gov/books /NBK22942/. Accessed March 24, 2016.
2. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287(5):612-617.
3. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of interest in clinical practice guideline development: a systematic review. PLoS One. 2011; 6(10):e25153. doi:10.1371/journal.pone.0025153.
4. Tibau A, Bedard PL, Srikanthan A, et al. Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs. J Clin Oncol. 2015;33(1):100-106. doi:10.1200/JCO .2014.57.8898.
5. Lerner TG, MirandaMda C, Lera AT, et al. The prevalence and influence of self-reported conflicts of interest by editorial authors of phase III cancer trials. Contemp Clin Trials. 2012;33(5):1019-1022. doi:10.1016/j.cct.2012.05.011.
6. Jones R, Ornstein C. Matching industry payments to Medicare prescribing patterns: an analysis. ProPublica. https://static.propublica.org /projects/d4d/20160317-matching-industry-payments.pdf?22. Published March 17, 2016. Accessed March 24, 2016.
7. Tillman K, Burton B, Jacques LB, Phurrough SE. Compendia and anticancer therapy under Medicare. Ann Intern Med. 2009;150(5):348-350.
8. Morain SR, Flexner C, Kass NE, Sugarman J. Forecast for the Physician Payment Sunshine Act: partly to mostly cloudy? Ann Intern Med. 2014;161 (12):915-916. doi:10.7326/M14-1683.
9. Marshall DC, Jackson ME, Hattangadi-Gluth JA. Disclosure of industry payments to physicians: an epidemiologic analysis of early data from the Open Payments Program. Mayo Clin Proc. 2016;91(1):84-96. doi:10.1016/j.mayocp.2015.10.016.
10. Centers for Medicare and Medicaid Services (CMS). Medicare, Medicaid, Children's Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests. February 2013. https://www.cms.gov /OpenPayments/Downloads/Affordable-Care-Act-Section-6002-Final-Rule.pdf. Accessed April 24, 2016.
11. Rosenbaum L. Beyond moral outrage: weighing the trade-offs of COI regulation. N Engl J Med. 2015; 372(21):2064-2068. doi:10.1056/NEJMms1502498.
12. Conflict of Interest Policy Implementation for Clinical Practice Guidelines of American Society of Clinical Oncology. August 2013. http://www.asco .org/sites/www.asco.org/files/conflict-of-interest-policy-implementation-for-clinical-practice-guidelines-8.8.2013.pdf. Accessed November 15, 2015.
13. Agrawal S, Brown D. The Physician Payments Sunshine Act: two years of the Open Payments Program. N Engl J Med. 2016;374(10):906-909. doi:10.1056/NEJMp1509103.
14. Oberlin DT, Gonzalez CM. Industry ties in medicine: insight from the open payments program. mayo clin proc. 2016;91(5):685-686. doi: 10.1016/j.mayocp.2016.02.003.
15. Ratain MJ. Forecasting unanticipated consequences of "the Sunshine Act": mostly cloudy. J Clin Oncol. 2014;32(22):2293-2295. doi:10.1200 /JCO.2014.55.4592.